BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 11896401)

  • 1. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.
    Pargellis C; Tong L; Churchill L; Cirillo PF; Gilmore T; Graham AG; Grob PM; Hickey ER; Moss N; Pav S; Regan J
    Nat Struct Biol; 2002 Apr; 9(4):268-72. PubMed ID: 11896401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The kinetics of binding to p38MAP kinase by analogues of BIRB 796.
    Regan J; Pargellis CA; Cirillo PF; Gilmore T; Hickey ER; Peet GW; Proto A; Swinamer A; Moss N
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3101-4. PubMed ID: 12941343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate.
    Regan J; Breitfelder S; Cirillo P; Gilmore T; Graham AG; Hickey E; Klaus B; Madwed J; Moriak M; Moss N; Pargellis C; Pav S; Proto A; Swinamer A; Tong L; Torcellini C
    J Med Chem; 2002 Jul; 45(14):2994-3008. PubMed ID: 12086485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitors.
    Kroe RR; Regan J; Proto A; Peet GW; Roy T; Landro LD; Fuschetto NG; Pargellis CA; Ingraham RH
    J Med Chem; 2003 Oct; 46(22):4669-75. PubMed ID: 14561086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
    Zaman GJ; van der Lee MM; Kok JJ; Nelissen RL; Loomans EE
    Assay Drug Dev Technol; 2006 Aug; 4(4):411-20. PubMed ID: 16945014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.
    Cirillo PF; Pargellis C; Regan J
    Curr Top Med Chem; 2002 Sep; 2(9):1021-35. PubMed ID: 12171569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural basis of inhibitor selectivity in MAP kinases.
    Wang Z; Canagarajah BJ; Boehm JC; Kassisà S; Cobb MH; Young PR; Abdel-Meguid S; Adams JL; Goldsmith EJ
    Structure; 1998 Sep; 6(9):1117-28. PubMed ID: 9753691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796).
    Regan J; Capolino A; Cirillo PF; Gilmore T; Graham AG; Hickey E; Kroe RR; Madwed J; Moriak M; Nelson R; Pargellis CA; Swinamer A; Torcellini C; Tsang M; Moss N
    J Med Chem; 2003 Oct; 46(22):4676-86. PubMed ID: 14561087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitor scaffolds as new allele specific kinase substrates.
    Kraybill BC; Elkin LL; Blethrow JD; Morgan DO; Shokat KM
    J Am Chem Soc; 2002 Oct; 124(41):12118-28. PubMed ID: 12371851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unique MAP Kinase binding sites.
    Akella R; Moon TM; Goldsmith EJ
    Biochim Biophys Acta; 2008 Jan; 1784(1):48-55. PubMed ID: 18068683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
    Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
    J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
    Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
    J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase.
    Wilson KP; McCaffrey PG; Hsiao K; Pazhanisamy S; Galullo V; Bemis GW; Fitzgibbon MJ; Caron PR; Murcko MA; Su MS
    Chem Biol; 1997 Jun; 4(6):423-31. PubMed ID: 9224565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and activity of new aryl- and heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain.
    Sawyer JS; Anderson BD; Beight DW; Campbell RM; Jones ML; Herron DK; Lampe JW; McCowan JR; McMillen WT; Mort N; Parsons S; Smith EC; Vieth M; Weir LC; Yan L; Zhang F; Yingling JM
    J Med Chem; 2003 Sep; 46(19):3953-6. PubMed ID: 12954047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket.
    Gum RJ; McLaughlin MM; Kumar S; Wang Z; Bower MJ; Lee JC; Adams JL; Livi GP; Goldsmith EJ; Young PR
    J Biol Chem; 1998 Jun; 273(25):15605-10. PubMed ID: 9624152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia.
    Branger J; van den Blink B; Weijer S; Madwed J; Bos CL; Gupta A; Yong CL; Polmar SH; Olszyna DP; Hack CE; van Deventer SJ; Peppelenbosch MP; van der Poll T
    J Immunol; 2002 Apr; 168(8):4070-7. PubMed ID: 11937566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure of JNK3 in complex with small molecule inhibitors: structural basis for potency and selectivity.
    Scapin G; Patel SB; Lisnock J; Becker JW; LoGrasso PV
    Chem Biol; 2003 Aug; 10(8):705-12. PubMed ID: 12954329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors.
    Dumas J; Hatoum-Mokdad H; Sibley R; Riedl B; Scott WJ; Monahan MK; Lowinger TB; Brennan C; Natero R; Turner T; Johnson JS; Schoenleber R; Bhargava A; Wilhelm SM; Housley TJ; Ranges GE; Shrikhande A
    Bioorg Med Chem Lett; 2000 Sep; 10(18):2051-4. PubMed ID: 10999468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.
    Young PR; McLaughlin MM; Kumar S; Kassis S; Doyle ML; McNulty D; Gallagher TF; Fisher S; McDonnell PC; Carr SA; Huddleston MJ; Seibel G; Porter TG; Livi GP; Adams JL; Lee JC
    J Biol Chem; 1997 May; 272(18):12116-21. PubMed ID: 9115281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.